Oligometastatic cancer has been recognized as a distinct clinical entity for over 100 years. For decades surgeons have been devising strategies to identify patients with oligmetastatic cancer that have the potential to be cured by surgically removing the oligometastases (“curative intent metastasectomy”). More recently, several studies have suggested there may be benefits to local therapy in oligometastatic cancer patients that are less likely to be cured. This has transformed the practice of local therapy in this setting away from “curative intent” to a broader purpose of “lesion-specific cytoreduction.” As a result, the pool of oligometastatic patients eligible for local therapy has been expanded. However, the boundaries that had previously framed the practice of local therapy in oligometastatic cancer have been obscured. The following is a single surgeon’s attempt to align the promise of this expanded role of local therapy, with the principles of risk-benefit deliberation that are intrinsic to the surgical discipline.

中文翻译：

---

外科医生对低转移性癌症局部治疗的观点。

已有100多年的历史，低位抑癌已被公认为是独特的临床实体。数十年来，外科医生一直在设计策略以鉴定具有通过外科手术切除低聚转移灶（“治愈性意图转移瘤”）治愈的潜力的低转移癌患者。最近，一些研究表明有可能是利益的局部治疗中oligometastatic癌症是不太可能被治愈的患者。在这种情况下，这已将局部疗法的实践从“治愈意图”转变为更广泛的“病变特异性细胞减少”的目的。结果，有资格接受局部治疗的少转移患者已扩展。但是，以前限制局部治疗在低转移性癌症中应用的界限已被掩盖。以下是单个外科医生试图将这种扩大的局部治疗作用的承诺与外科学科固有的风险收益审议原则进行统一的尝试。